S-ICD Sales Exceeding Expectations, Boston Scientific Reports
This article was originally published in The Gray Sheet
Executive Summary
The company said when S-ICD launched that it expected the device to be a major growth driver, and that appears to be working out so far. Boston Scientific now expects the leadless implantable defibrillator to bring in $100 million in revenue this year.